Abstract
After severe brain injury, it can be difficult to determine the state of consciousness of a patient, to determine whether the patient is unresponsive or perhaps minimally conscious1, and to predict whether they will recover. These diagnoses and prognoses are crucial, as they determine therapeutic strategies such as pain management, and can underlie end-of-life decisions2,3. Nevertheless, there is an error rate of up to 40% in determining the state of consciousness in patients with brain injuries4,5. Olfaction relies on brain structures that are involved in the basic mechanisms of arousal6, and we therefore hypothesized that it may serve as a biomarker for consciousness7. Here we use a non-verbal non-task-dependent measure known as the sniff response8–11 to determine consciousness in patients with brain injuries. By measuring odorant-dependent sniffing, we gain a sensitive measure of olfactory function10–15. We measured the sniff response repeatedly over time in patients with severe brain injuries and found that sniff responses significantly discriminated between unresponsive and minimally conscious states at the group level. Notably, at the single-patient level, if an unresponsive patient had a sniff response, this assured future regaining of consciousness. In addition, olfactory sniff responses were associated with long-term survival rates. These results highlight the importance of olfaction in human brain function, and provide an accessible tool that signals consciousness and recovery in patients with brain injuries.
Original language | English |
---|---|
Pages (from-to) | 428-433 |
Number of pages | 6 |
Journal | Nature |
Volume | 581 |
Issue number | 7809 |
DOIs | |
State | Published - 28 May 2020 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Funding
Acknowledgements We thank the patients, their families and their caregivers for their cooperation; and O. Perl, L. Rösler and A. Elite for discussions. Work in the Sobel laboratory is supported by the Rob and Cheryl McEwen Fund for Brain Research. A.A. is supported by the Blavatnik Family Foundation, a Royal Society – Kohn International fellowship (NF150851) and an European Molecular Biology Organization (EMBO) fellowship (ALTF 33-2016).
Funders | Funder number |
---|---|
European Molecular Biology Organization | ALTF 33-2016 |
Blavatnik Family Foundation | |
Royal Society | NF150851 |